Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07404605 | Electrochemotherapy-Induced Changes in Tumor Microenvironment in Cutaneous Melanoma | recruiting | N/A | 150 | Institute of Oncology LjubljanaOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07421739 | Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects | recruiting | — | 15 | Aura BiosciencesINDUSTRY | 1 | Feb 19, 2026 | clinicaltrials |
| NCT05384496 | Axitinib and Nivolumab for the Treatment of Mucosal Melanoma | recruiting | Phase 2 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04567706 | A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma | recruiting | — | 1,000 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05987332 | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | active not recruiting | Phase 2 / Phase 3 | 420 | IDEAYA BiosciencesINDUSTRY | 13 | Feb 17, 2026 | clinicaltrials |
| NCT07403630 | INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)(IT-TCP POS) | recruiting | N/A | 300 | Azienda Ospedaliero-Universitaria di ParmaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07407166 | Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers | recruiting | N/A | 40 | Institute of Oncology LjubljanaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03767348 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)(IGNYTE) | active not recruiting | Phase 2 | 340 | Replimune, Inc.INDUSTRY | 5 | Feb 13, 2026 | clinicaltrials |
| NCT04903119 | Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma | recruiting | Phase 1 | 30 | Rina PlattnerOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07406724 | HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma | not yet recruiting | Phase 2 | 90 | Qingdao Sino-Cell Biomedicine Co., Ltd.INDUSTRY | 0 | Feb 12, 2026 | clinicaltrials |
| NCT06190951 | A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma | active not recruiting | Phase 2 | 151 | Regeneron PharmaceuticalsINDUSTRY | 8 | Feb 10, 2026 | clinicaltrials |
| NCT04478279 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Sapience TherapeuticsINDUSTRY | 2 | Feb 9, 2026 | clinicaltrials |
| NCT06432660 | Eye Plaque Brachytherapy for Ocular Melanoma(PROMPT) | active not recruiting | — | 42 | Duke UniversityOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03543969 | Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma | active not recruiting | Early Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05418972 | A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma(Neo ReNi II) | active not recruiting | Phase 2 | 20 | Melanoma Institute AustraliaOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03340129 | Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)(ABC-X) | recruiting | Phase 2 | 218 | Melanoma Institute AustraliaOTHER | 2 | Feb 2, 2026 | clinicaltrials |
| NCT04645680 | Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy(DIET) | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT03474497 | UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | active not recruiting | Phase 1 / Phase 2 | 18 | Megan Daly, MDOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05121545 | Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors(ProGRID) | active not recruiting | N/A | 11 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07376317 | Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)(OTIMAS) | active not recruiting | Phase 2 | 29 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07376512 | Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis(EVpredict) | not yet recruiting | — | 378 | Centre Georges Francois LeclercOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07376707 | A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors(TGI5) | recruiting | Phase 1 | 194 | Hefei TG ImmunoPharma Co., Ltd.OTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | active not recruiting | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07138222 | IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma(IMPACT) | recruiting | — | 80 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 266 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06599619 | Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi | recruiting | — | 30 | John KirkwoodOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT03891953 | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | active not recruiting | Phase 1 | 98 | Novartis PharmaceuticalsINDUSTRY | 6 | Jan 21, 2026 | clinicaltrials |
| NCT07221734 | Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma | recruiting | Phase 3 | 632 | mAbxience Research S.L.INDUSTRY | 2 | Jan 21, 2026 | clinicaltrials |
| NCT06199713 | Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients | recruiting | — | 24 | University of Wisconsin, MadisonOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05529316 | A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma | active not recruiting | Phase 2 | 150 | Agenus Inc.INDUSTRY | 10 | Jan 16, 2026 | clinicaltrials |
| NCT06717126 | A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma(OCULE-01) | active not recruiting | Phase 2 | 85 | iOncturaINDUSTRY | 3 | Jan 16, 2026 | clinicaltrials |
| NCT07347444 | Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma | not yet recruiting | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT00582647 | Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract | active not recruiting | — | 6,000 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07318051 | Sample Collection for Ongoing Research and Product Evaluation Study(SCORE) | recruiting | — | 9,600 | Natera, Inc.INDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07336979 | Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma | recruiting | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT03829254 | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | recruiting | Phase 1 / Phase 2 | 135 | NuCana plcOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06054555 | A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma | active not recruiting | Phase 3 | 633 | AmgenINDUSTRY | 31 | Jan 12, 2026 | clinicaltrials |
| NCT06887348 | A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3(RPx) | recruiting | — | 50 | Replimune, Inc.INDUSTRY | 2 | Jan 12, 2026 | clinicaltrials |
| NCT05902520 | Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors(ACT) | active not recruiting | Phase 1 | 18 | AgonOx, Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06946225 | ACTengine® IMA203 Combined With mRNA-4203 | recruiting | Phase 1 | 15 | Immatics US, Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07161310 | Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors(MitoCancer) | recruiting | N/A | 45 | Goethe UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT07320222 | CARE-Melanoma Trial(CARE-Melanoma) | not yet recruiting | Phase 1 | 30 | McMaster UniversityOTHER | 0 | Jan 6, 2026 | clinicaltrials |
| NCT03929029 | Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma | active not recruiting | Phase 1 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05428007 | Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma | recruiting | Phase 2 | 105 | NYU Langone HealthOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT01266096 | PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study | active not recruiting | N/A | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05307289 | Study of Alterations in Tumor Metabolism Associated With the Development of Immunotherapy Resistance in Melanoma(MEL-META) | recruiting | N/A | 20 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Dec 31, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 19, 2026source: clinicaltrials